Pharma's Promising Path in COPD Treatment
Source: Streetwise Reports (04/26/2024)
As Verona Pharma releases more news surrounding its COPD treatments, analysts are taking notice. Read to see what Verona is doing in the pharmaceutical space and what three analysts have to say about this company's stock.
read more >
AI Healthcare Stock Has Bullish Setup, Expert Says
Source: Clive Maund (04/22/2024)
Technical Analyst Clive Maund reviews Treatment.com AI's charts and the recent influx of news to explain why he believes it is a Strong Buy.
read more >
Biopharma's New Drug for COPD Likely to be Approved
Source: Ram Selvaraju (04/22/2024)
Characteristics of the Buy-rated company's lead candidate make it "an intriguing commercial prospect," noted an H.C. Wainwright & Co. report.
read more >
PDUFA Date Coming Up for U.K. Biopharma
Source: Edward Nash (04/22/2024)
The company has a commercialization plan in place and is preparing further for approval, noted a Canaccord Genuity report.
read more >
Analyst Says Pharma Co. Has No True Competitor
Source: Andrew Tsai (04/19/2024)
Verona Pharma Plc. recently is gearing up for a potential FDA approval of its twice-daily ensifentrine, according to a Jefferies & Co. research note.
read more >